Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use
A technology of calcium ion antagonist and telmisartan, applied in the field of pharmaceutical compounds, can solve problems such as low treatment rate and control rate, and achieve the effects of less adverse reactions, less fluctuation of blood drug concentration, and longer duration of action
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] 1. Materials and methods
[0030] 1.1 Case selection: Mild to moderate hypertensive patients aged 18 to 65 in outpatient and inpatient, sitting diastolic blood pressure 95 to 115 mmHg, systolic blood pressure <200 mmHg, not accompanied by serious target organ damage, male or female. The diagnosis of hypertension was in line with WHO criteria. The following conditions are excluded: severe liver or kidney dysfunction, severe alcohol and tobacco addiction, pregnant women, breastfeeding women, and those who have been ineffective or intolerable to the above-mentioned drug treatments in the past.
[0031] 1.2 Test method: All 120 patients stopped using other drugs that affect blood pressure for more than 5 half-lives before treatment, asked about medical history and various examinations in detail, except for secondary hypertension. They were randomly divided into 4 groups: ① low-low dose combination group: amlodipine (Aml, Pfizer Pharmaceutical Co., Ltd.) 2.5 mg / telmisartan...
Embodiment 2
[0044] 1. Materials and methods
[0045] 1.1 Case selection:
[0046] Mild to moderate hypertensive patients aged 18 to 65 in outpatient or hospital, sitting diastolic blood pressure 95 to 115mmHg, systolic blood pressure <200mmHg, not accompanied by serious target organ damage, male or female. The diagnosis of hypertension was in line with WHO criteria. The following conditions are excluded: severe liver or kidney dysfunction, severe alcohol and tobacco addiction, pregnant women, breastfeeding women, and those who have been ineffective or intolerable to the above-mentioned drug treatments in the past.
[0047] 1.2 Test method: All 150 patients stopped using other drugs that affect blood pressure for more than 5 half-lives before treatment, asked about medical history and various examinations in detail, except for secondary hypertension. Randomly divided into 3 groups: ① low-low dose combination group: levamlodipine (Lam, Tianfeng Pharmaceutical Co., Ltd.) 1.25 mg / telmisart...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com